Evolent Health

Evolent Health, Inc. engages in the provision of health care delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evolent Health excels in Q4 2022, eyes growth with Humana

Evolent Health posts strong financials, exceeding revenue and EBITDA targets.
Strategic partnerships and focus on organic growth drive value creation.
Challenges lie in maintaining growth momentum and effective execution.
Opportunities include margin expansion, capital optimization, and Humana partnerships.

Evolent Health surpasses Q1 expectations, eyes revenue growth opportunities

Evolent Health's Q1 performance exceeded expectations, driven by strong revenue growth and margin expansion initiatives. While facing challenges like revenue adjustments and Medicaid rebates, the company remains focused on capitalizing on growth opportunities through strategic partnerships and operational efficiencies.

Evolent Health excels in Q2, eyes $300M EBITDA target

Evolent Health's robust performance in Q2, strategic partnerships, and focus on organic growth position it well to achieve its financial targets.
Challenges lie in Medicaid membership declines, capital allocation optimization, and refinancing decisions amidst market uncertainties.
Opportunities in patient-centric care, CMS changes, and integrated entity approach offer avenues for growth and differentiation in the market.

Evolent Health surpasses Q3 expectations, eyes growth in specialty care

Evolent Health's Q3 performance exceeded expectations, driven by strong revenue growth and profitability, underpinned by strategic partnerships and a unique care model.
Despite challenges in ramping up Performance Suite adoption and maintaining cost control, the company's focus on growth and value creation positions it well for future success.
Opportunities in expanding specialty offerings and leveraging new partnerships highlight Evolent's growth potential and commitment to delivering value in the healthcare sector.

Evolent Health exceeds 2023 targets, eyes growth through partnerships

Evolent Health delivered strong financial results in Q4 2023, surpassing its 2023 targets and setting ambitious goals for 2024, driven by Specialty Care offerings and new revenue agreements.
While facing challenges related to medical utilization and new product launches, the company remains focused on organic growth and profitability, supported by a strategic approach to expansion.
Opportunities in cross-selling, new state expansions, and imaging capabilities position Evolent Health for continued growth and revenue diversification in the healthcare sector.

Evolent Health reports robust Q1 earnings, eyes margin improvements

Evolent Health's Q1 performance showcased strong revenue growth and EBITDA in line with guidance.
The company is optimistic about margin improvements, revenue expansion, and maintaining a balanced pipeline.
Challenges include margin impact from new go-lives and ongoing payer negotiations amid cost pressures.
Opportunities lie in improving gross margins, leveraging population changes, and focusing on cash flow expectations.

Evolent Health reports robust Q2 earnings, eyes growth opportunities ahead

Evolent Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives, and a positive outlook for future growth. The company's focus on revenue diversification, margin optimization, and disciplined financial management positions it well for continued success in the evolving healthcare landscape.

Evolent Health revises outlook after Q3 challenges, secures financing

Evolent Health navigated higher medical costs impacting Q3 results, leading to a revised outlook for 2024. Despite challenges in managing expenses and oncology costs, the company remains committed to growth and securing new revenue agreements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

Dr. Ajayi becomes the ninth independent board member; adds exceptional, relevant expertise as a CEO, physician, entrepreneur and advocate for improving health care quality and cost for underserved populations. WASHINGTON , July 26, 2023 /PRNewswire/ -- Evolent Health Inc. (NYSE: EVH), a health care company that delivers proven value-based specialty care solutions to payers and providers, announced today that its Board of Directors has appointed Toyin Ajayi, M.D.

Evolent welcomes Toyin Ajayi to its Board of Directors

Evolent Health's sales and profitability are creeping back above pre-pandemic levels. The company's recent acquisitions have added incremental value, with revenues up 44% YoY and adjusted EBITDA up 94% with their inclusion. Net-net, reiterate buy.

Evolent Health: Business Economics Still Appealing, Reiterate Buy

WASHINGTON , July 13, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven value-based specialty care solutions to payers and providers, announced today that it will release its second quarter 2023 financial results on Wednesday, August 2, 2023, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 855.940.9467 or 412.317.6034 for international callers and referencing the "Evolent call" 15 minutes prior to the call.

Evolent to Release Second Quarter Financial Results on Wednesday, August 2, 2023

Growth-focused company is a trusted partner for health plans and providers seeking to improve health outcomes across complex conditions. WASHINGTON , July 11, 2023 /PRNewswire/ -- Evolent Health ("the Company") (NYSE: EVH), a health care company that delivers proven value-based specialty care solutions to payers and providers, announced today that it is rebranding as Evolent and will integrate its portfolio of solutions and businesses under that name by year's end.

Evolent Health announces focus on value-based specialty care with rebrand, unification of all solutions under "Evolent"

Evolent Health, Inc. (NYSE:EVH ) Q1 2023 Results Conference Call May 3, 2023 5:00 PM ET Company Participants Seth Frank - VP, IR Seth Blackley - CEO John Johnson - CFO Conference Call Participants Sandy Draper - Guggenheim Partners Anne Samuel - JP Morgan Charles Rhyee - TD Cowen David Larsen - BTIG Jailendra Singh - Truist Jeff Garro - Stephens Jessica Tassan - Piper Sandler Richard Close - Canaccord Genuity Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Operator Welcome to Evolent Health's Earnings Conference Call for the Quarter Ended March 31, 2023. As a reminder, this conference call is being recorded.

Evolent Health, Inc. (EVH) Q1 2023 Earnings Call Transcript

Evolent Health (EVH) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago.

Evolent Health (EVH) Beats Q1 Earnings Estimates

WASHINGTON , May 3, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended March 31, 2023. Highlights from the first quarter 2023 announcement include: Revenue of $427.7 million, an increase of $130.6 million, or 44.0%, from the three months ended March 31, 2022.

Evolent Health Announces First Quarter 2023 Results

Richard Jelinek nominated to join the Board; current director David Farner to depart the Board in June 2023, in addition to previously announced departure of Frank Williams. WASHINGTON , April 19, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven specialty clinical solutions to payers and providers, today announced that a new director nominee will stand for election to the Board of Directors at the annual meeting of stockholders scheduled to be held on June 8, 2023.

Evolent Health Names New Independent Nominee for Election to Board of Directors

Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven specialty clinical solutions to payers and providers, today announced it will release its first quarter 2023 financial results on Wednesday, May 3, 2023, after market close, with a conference call to follow at 5 p.m. ET.

Evolent Health to Release First Quarter Financial Results on Wednesday, May 3, 2023

Centene

WASHINGTON , March 29, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven value-based specialty care solutions to payers and providers, today announced an agreement to expand its Technology and Services solution for oncology with its existing partner, Centene Corporation, (NYSE: CNC).  Centene will expand its use of Evolent Health's oncology solution across its Centene and WellCare Medicare Advantage (MA) members nationally.

Evolent Health and Centene Agree to Expanded Partnership for Oncology Specialty Care for Medicare Advantage Members

Evolent Health, Inc. (NYSE:EVH ) Q4 2022 Earnings Conference Call February 22, 2023 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Anne Samuel - JPMorgan Ryan Daniels - William Blair David Larsen - BTIG Sandy Draper - Guggenheim Richard Close - Canaccord Genuity Jailendra Singh - Truist Jessica Tassan - Piper Sandler Charles Rhyee - Cowen Operator Welcome to Evolent Health's Earnings Conference Call for the Fourth Quarter and Year ended December 31, 2022. As a reminder, this conference call is being recorded.

Evolent Health, Inc. (EVH) Q4 2022 Earnings Call Transcript

Evolent Health (EVH) delivered earnings and revenue surprises of 66.67% and 2.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Evolent Health (EVH) Surpasses Q4 Earnings and Revenue Estimates

WASHINGTON , Feb. 22, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended December 31, 2022. Highlights from the fourth quarter and full year 2022 announcement include: Quarter ended December 31, 2022: Revenue of $382.4 million, an increase of $134.1 million, or 54.0%, from the three months ended December 31, 2021.

Evolent Health Announces Fourth Quarter and Full Year 2022 Results

Evolent Health is a high growth stock that has rewarded shareholders with tremendous upside. The company has been reinvesting heavily into its growth initiatives at high rates of return.

Evolent Health: Strengthening Fundamentals, Investing At High Rates Of Return

WASHINGTON , Jan. 31, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its fourth quarter 2022 financial results on Wednesday, February 22, 2023 after market close, with a conference call to follow at 5:00 p.m. Eastern Time.

Evolent Health, Inc. to Release Fourth Quarter Financial Results and Host Conference Call on Wednesday, February 22, 2023

Evolent Health announced its next deal, intensifying its relationship with Centene in the meantime. The deal is a bit complicated but has potential, as underlying sales growth has been accelerating.

Evolent Health: A Bit Complex, But Interesting

Investors are applauding Evolent's latest acquisition.

Why Evolent Health Stock Is Soaring Today

Centene Corp. CNC, +1.79% said late Thursday it has agreed to sell its Magellan Specialty Health benefit-management business to Evolent Health Inc. EVH, +0.21% for $750 million, lauding it as a "milestone" in the health insurer's "value creation program and ongoing portfolio review." Centene bought Magellan Specialty Heath in January as part of its acquisition of Magellan Health, Inc. Upon the deal's closing, Centene and Evolent plan to launch a national multi-year partnership, the company said.

Centene agrees to sell benefit-management unit to Evolent Health for $750 million

Accelerates Evolent Health's Value-Based Specialty Care Market Leadership Transaction Anticipated to be Immediately Accretive to Adjusted EBITDA Margins and Cash Flow Highly Complementary Business Expected to Add $85 Million of High-Visibility Adjusted EBITDA by 2024; Maintains Strong Balance Sheet Diversifies Evolent's Revenue Base and Increases Cross-Sell Opportunity from $16 Billion to $50 Billion Expands Centene Customer Relationship with New NIA Contract Expansions and is Expected to Accelerate Pace of Remaining Evolent Cross-Sell Opportunity with Centene WASHINGTON , Nov. 17, 2022 /PRNewswire/ -- Evolent Health, Inc. ("Evolent" or "the Company") (NYSE: EVH) today announced that it has entered into a definitive agreement to acquire NIA (also known as Magellan Specialty Health), the specialty benefit management organization owned by Centene Corporation (NYSE: CNC) that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine, and genetics. NIA has revenues of approximately $250 million and stand-alone Adjusted EBITDA of approximately $50 million.

EVOLENT HEALTH ANNOUNCES ACQUISITION OF SPECIALTY ASSET NIA AND STRATEGIC PARTNERSHIP WITH CENTENE

For the second time in nearly as many days, the company's shares got a price target haircut.

Why Evolent Health Stock Sank by Over 6% Today

Evolent Health (EVH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 29.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolent Health (EVH)

Call Start: 18:03 Evolent Health, Inc. (NYSE:EVH ) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Anne Samuel - JPMorgan Charles Rhyee - Cowen & Co. Sean Dodge - RBC Capital Markets Ryan Daniels - William Blair Sandy Draper - Guggenheim David Larsen - BTIG Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Jailendra Singh - Truist Securities Operator Welcome to Evolent Health's Earnings Conference Call for the Third Quarter Ended September 30, 2022. As a reminder, this conference call is being recorded.

Evolent Health, Inc. (EVH) Q3 2022 Earnings Call Transcript

Evolent Health (EVH) delivered earnings and revenue surprises of 637.50% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Evolent Health (EVH) Q3 Earnings Top Estimates

WASHINGTON , Nov. 2, 2022 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended September 30, 2022. Highlights from the third quarter of 2022 announcement include: Quarter ended September 30, 2022: Revenue of $352.6 million, an increase of $130.1 million, or 58.5%, from the three months ended September 30, 2021.

Evolent Health Announces Third Quarter 2022 Results

Here is how Evolent Health (EVH) and KVH Industries (KVHI) have performed compared to their sector so far this year.

News for Evolent Health Stock (EVH)